Antagonism of cytotoxic T-lymphocyte activation by soluble CD8

The CD8 co-receptor is important in the differentiation and selection of class I MHC-restricted T cells during thymic development, and in the activation of mature T lymphocytes in response to antigen. Here we show that soluble CD8αα receptor, despite an extremely low affinity for MHC, inhibits activation of cytotoxic lymphocytes by obstructing CD3 ζ-chain phosphorylation. We propose a model for this effect that involves interference of productive receptor multimerization at the T-cell surface. These results provide new insights into the mechanism of T-cell activation and evidence that CD8 function is exquisitely sensitive to disruption, an effect that might be exploited by molecular therapeutics.

[1]  Ellis L. Reinherz,et al.  The differentiation and function of human T lymphocytes , 1980, Cell.

[2]  P. Doherty.  T cells and viral infections. , 1985, British medical bulletin.

[3]  Effector Mechanisms in Allograft Rejection , 1986 .

[4]  受體（Receptor）醫學 , 1987 .

[5]  C. Bieberich,et al.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. , 1988, Annual review of immunology.

[6]  P. Parham,et al.  Cell-cell adhesion mediated by CD8 and MHC class I molecules , 1988, Nature.

[7]  Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. , 1989, Leukemia.

[8]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[9]  P. Kavathas,et al.  A secreted form of the human lymphocyte cell surface molecule CD8 arises from alternative splicing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Zambello,et al.  Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. , 1989, Clinical immunology and immunopathology.

[11]  C. Zielinski,et al.  Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. , 1990, Clinical immunology and immunopathology.

[12]  R. Perlmutter,et al.  Interaction of the unique N-terminal region of tyrosine kinase p56 lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs , 1990, Cell.

[13]  A. O'Rourke,et al.  Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling , 1990, Nature.

[14]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. , 1990, Nature.

[15]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 , 1990, Nature.

[16]  T. Potter,et al.  Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Mak,et al.  CD8 is needed for development of cytotoxic T cells but not helper T cells. , 1991, Cell.

[18]  T. Mak,et al.  CD8 is needed for development of cytotoxic T but not helper T cells , 1991, Cell.

[19]  A. Reder,et al.  Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis , 1991, Neurology.

[20]  P. Parham,et al.  CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68. 1 , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[21]  Phosphorylation of murine CD8α is not essential for responses of T cell hybridomas to antigen , 1991 .

[22]  R. Perlmutter,et al.  Participation of CD4 coreceptor molecules in T-cell repertoire selection , 1991, Nature.

[23]  N. Shastri,et al.  Requirement for association of p56 lck with CD4 in antigen-specific signal transduction in T cells , 1991, Cell.

[24]  Phosphorylation of murine CD8 alpha is not essential for responses of T cell hybridomas to antigen. , 1991, International immunology.

[25]  H. Grey,et al.  Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor , 1992, Cell.

[26]  S. Cobbold,et al.  Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies , 1992, Immunological reviews.

[27]  R. Perlmutter,et al.  Disruption of CD8‐dependent negative and positive selection of thymocytes is correlated with a decreased association between CD8 and the protein tyrosine kinase, p56lck , 1992, European journal of immunology.

[28]  A. O'Rourke,et al.  Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events , 1992, Nature.

[29]  D. Littman,et al.  Requirement for CD8-major histocompatibility complex class I interaction in positive and negative selection of developing T cells , 1992, The Journal of experimental medicine.

[30]  H. Pircher,et al.  CD8 is needed for positive selection but differentially required for negative selection of T cells during thymic ontogeny , 1993, European journal of immunology.

[31]  W. Fung-Leung,et al.  Thymic selection of cytotoxic T cells independent of CD8 alpha-Lck association. , 1993, Science.

[32]  M. Bevan,et al.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells , 1993, The Journal of experimental medicine.

[33]  R. Zamoyska,et al.  Is CD8 dependence a true reflection of TCR affinity for antigen? , 1993, International immunology.

[34]  Sarah Rowland-Jones,et al.  Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.

[35]  R. Zinkernagel,et al.  Promethean viruses? , 1994, Nature.

[36]  Zinkernagel Rm,et al.  Immunology - Promethean Viruses , 1994 .

[37]  R. Zamoyska,et al.  The CD8 coreceptor revisited: one chain good, two chains better. , 1994, Immunity.

[38]  J. Klinenberg,et al.  Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. , 1994, Journal of immunology.

[39]  C. Janeway,et al.  Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. , 1994, Immunity.

[40]  A. Sette,et al.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.

[41]  P. Romero,et al.  CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes , 1995, Nature.

[42]  A. Kleinfeld,et al.  T cell receptor and CD8‐dependent tyrosine phosphorylation events in cytotoxic T lymphocytes: activation of p56lck by CD8 binding to class I protein , 1996, European journal of immunology.

[43]  P. A. Peterson,et al.  CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes , 1996, Nature.

[44]  Y. Chien,et al.  A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. , 1996, Immunity.

[45]  Partho Ghosh,et al.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.

[46]  Antonio Lanzavecchia,et al.  T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds , 1996, Science.

[47]  D. Stuart,et al.  Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. , 1997, Nature.

[48]  D. Stuart,et al.  Crystal structure of the complex between human CD8αα and HLA-A2 , 1997, Nature.

[49]  Y. Chien,et al.  CD4 augments the response of a T cell to agonist but not to antagonist ligands. , 1997, Immunity.

[50]  J. Cerottini,et al.  Effects of Epitope Modification on T Cell Receptor–Ligand Binding and Antigen Recognition by Seven H-2Kd–restricted Cytotoxic T Lymphocyte Clones Specific for a Photoreactive Peptide Derivative , 1997, The Journal of experimental medicine.

[51]  R. Phillips,et al.  Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides , 1997, European journal of immunology.

[52]  T. Preckel,et al.  Altered Hapten Ligands Antagonize Trinitrophenyl-specific Cytotoxic T Cells and Block Internalization of Hapten-specific Receptors , 1997, The Journal of experimental medicine.

[53]  P. Klenerman,et al.  The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection , 1998, Journal of Molecular Medicine.

[54]  S. Rowland-Jones,et al.  Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. , 1998, Current biology : CB.

[55]  S. Rowland-Jones,et al.  Antigen–specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes , 1998, Current Biology.

[56]  J. Altman,et al.  Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. , 1998, Immunity.

[57]  R. Korngold,et al.  A structure-based approach to designing synthetic CD8α peptides that can inhibit cytotoxic T-lymphocyte responses , 1998, Nature Medicine.

[58]  Mark M. Davis,et al.  LIGAND RECOGNITION BY T CELL RECEPTORS , 1998 .

[59]  P. Klenerman,et al.  Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P. Allen,et al.  Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. , 1998, Science.

[61]  Z Reich,et al.  Ligand recognition by alpha beta T cell receptors. , 1998, Annual review of immunology.

[62]  B K Jakobsen,et al.  T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. , 1999, Immunity.